Pharmacological cancer treatment and venous thromboembolism risk
Por:
Martin, AJM, Ramirez, SP, Moran, LO, Zamorano, MR, Beneitez, MCV, Salcedo, IA, Escobar, IG, Fernandez, JMS
Publicada:
1 abr 2020
Resumen:
Risk factors for cancer-associated thrombosis are commonly divided into three categories: patient-, cancer-, and treatment-related factors. Currently, different types of drugs are used in cancer treatment. Chemotherapy has been identified as an independent risk factor for venous thromboembolism (VTE). However, it should be noted, that the risk of VTE is not consistent among all cytotoxic agents. In addition, different supportive care drugs, such as erythropoiesis stimulating agents or granulocyte colony stimulating factors, and hormonotherapy have been associated to an increased risk of VTE. Immunotherapy and molecular-targeted therapies have significantly changed the treatment of cancer over the past decade. The main subtypes include tyrosine-kinase inhibitors, monoclonal antibodies, small molecules, and immunomodulatory agents. The relationship between VTE and targeted therapies remains largely unknown.
Filiaciones:
Martin, AJM:
Hosp Gen Univ Gregorio Maranon, Med Oncol Dept, Calle Doctor Esquerdo 46, Madrid 28007, Spain
Ramirez, SP:
Hosp Gen Univ Gregorio Maranon, Med Oncol Dept, Calle Doctor Esquerdo 46, Madrid 28007, Spain
Moran, LO:
Hosp Gen Univ Gregorio Maranon, Med Oncol Dept, Calle Doctor Esquerdo 46, Madrid 28007, Spain
Zamorano, MR:
Univ Complutense, Fac Med, Dept Med, Av Seneca 2, Madrid 28040, Spain
Beneitez, MCV:
Univ Complutense, Fac Med, Dept Med, Av Seneca 2, Madrid 28040, Spain
Salcedo, IA:
Hosp Gen Univ Gregorio Maranon, Med Oncol Dept, Calle Doctor Esquerdo 46, Madrid 28007, Spain
Escobar, IG:
Hosp Gen Univ Ciudad Real, Med Oncol Dept, Calle Obispo Rafael Torija S-N, Ciudad Real 130050, Spain
Fernandez, JMS:
Inst Invest St Pau IIB St PAU, Genom Complex Dis Unit, Joan Alcover 7-2 2a, Barcelona 08031, Spain
hybrid, Green Published
|